Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib

Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non‐small cell lung cancer (NSCLC). Here, we report the case of a 60‐year‐old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yuan, Yu, Qing, Xiong, Yan, Guo, Cuiyan, Nie, Ligong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919124/
https://www.ncbi.nlm.nih.gov/pubmed/33438350
http://dx.doi.org/10.1111/1759-7714.13785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919124/
https://www.ncbi.nlm.nih.gov/pubmed/33438350
http://dx.doi.org/10.1111/1759-7714.13785

Ejemplares similares